-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $30

Benzinga·09/08/2026 11:21:14
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $24 to $30.